Market Overview

Lazard Capital Markets Initiated Coverage on Nektar Therapeutics at Buy, Announced $15.00 PT

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for NKTR

DateFirmActionFromTo
Mar 2015JefferiesMaintainsBuy
Mar 2015JP MorganMaintainsOverweight
Sep 2014Bank of AmericaMaintainsUnderperform

View More Analyst Ratings for NKTR
View the Latest Analyst Ratings

Posted-In: News Analyst Ratings

 

Related Articles (NKTR)

Get Benzinga's Newsletters